Tatiana A. Panafidina

Tatiana A. Panafidina

Auto-generated profile, based on publicly available information

Tatiana A. Panafidina

V.A. Nasonova Research Institute of Rheumatology

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2021 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
ENE. L. Nasonov
E. L. Nasonov
TVTatyana Popkova V.
Tatyana Popkova V.
TPT. A. Panafidina
T. A. Panafidina
Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease of unknown etiology, characterized by overproduction of organ-nonspecific autoantibodies to various components of the cell nucleus and cytoplasm and the development of immune-inflammatory damage to internal organs. The debut of SLE is preceded by an asymptomatic period, characterized by impaired immunological tolerance to its own autoantigens, determined by the multifaceted interaction of external, genetic and epigenetic factors, hormonal disorders, microbiome pathology, stress effects, etc. Development of a certain spectrum of clinical symptoms characteristic of SLE along with the detection of a reflects the progression of the immunopathological process in SLE, however, there is no generally accepted term that defines the patient’s condition, which has individual serological and clinical signs characteristic of this disease. In rheumatology, the concept of «incomplete» SLE is currently most often used. The problems of early diagnosis of SLE, clinical and laboratory predictors of the transformation of “incomplete” SLE into “reliable” SLE, difficulties in diagnosing SLE during the COVID-19 pandemic are considered. Particular attention is paid to the comparative characteristics of the immunopathological mechanisms of SLE and COVID-19.

1 January 2021 in Doctor.Ru
Verified
Journal Article
Open access
TPT.A. Panafidina
T.A. Panafidina
VRV.A. Nasonova Scientific and Research Institute of Rheumatology
V.A. Nasonova Scientific and Research Institute of Rheumatology
TVTatyana Popkova V.
Tatyana Popkova V.
EAE.A. Aseeva
E.A. Aseeva
ALAleksandr M Lila
Aleksandr M Lila
RMRussian Federation Moscow
Russian Federation Moscow
Современный подход в диагностике и лечении системной красной волчанки. «Доктор.Ру» - научно-практический медицинский рецензируемый журнал для врачей, ученых и преподавателей медицинских вузов.

1 January 2022 in Doctor.Ru
Verified
Journal Article
Open access
TPT.A. Panafidina
T.A. Panafidina
VRV.A. Nasonova Research Institute of Rheumatology
V.A. Nasonova Research Institute of Rheumatology
TVTatyana Popkova V.
Tatyana Popkova V.
LKL.V. Kondratieva
L.V. Kondratieva
RMRussian Federation Moscow
Russian Federation Moscow
Study Objective: To identify the structure and prevalence of cardiac involvement in patients with systemic lupus erythematosus (SLE); evaluation of the relationship with the activity, disease duration and antirheumatic therapy. Study Design: Prospective cross-sectional study. Material and Methods. The study included 87 patients with SLE (90.8% women), with the median age of 32 [28; 41] years old and disease duration of 6 [1; 10] years; Systemic Lupus Erythematosus Disease Activity Index, modification 2К, was 9 [4; 16] points, Systemic Lupus International Collaborating Clinics Damage Index was 0 [0; 1] points. All patients were examined by a cardiologist, and traditional risk factors (TRF) of cardiovascular diseases were identified. Patients underwent transthoracic echocardiography (ECHO); if indicated, 24-hour ECG and blood pressure monitoring was performed. Serum NT-proBNP concentration was measured with electrochemiluminescence. Study Results. The most common cardiac complication was valvular insufficiency with various degree of regurgitation, which was diagnosed in 92% patients; endocarditis was recorded in 30%; mitral or tricuspid valve prolapse was observed in 33.3%. Pericardium pathologies were diagnosed in 44.8% patients, and adhesive pericarditis prevailed (61.5%). Myocarditis was observed in 4.6%, ischemic heart disease (IHD) — in 5.7%, cardiac failure (CF) — in 11.5%, rhythm and cardiac conduction disturbances — in 18.4% and 2.3%, respectively, myocardial infarction (MI) — in 2.3%. Dislipidemy and arterial hypertension (AH) were recorded in 50.6% and 46% patients. 31% demonstrated high NT-proBNP levels (> 125.0 pg/mL); median NT-proBNP concentration was 91.8 [27.1–331.2] pg/mL. Patients were divided into two groups: group 1 did not take any glucocorticoids (GC), immunosuppressants and genetically engineered biologic drugs; group 2 had various combinations of these products. Patients in both groups were of similar age and sex; they did not have any differences in the prevalence of valvular insufficiency (86.7% and 97.6%), endocarditis (26.2% and 33.3%), pericarditis (42.9% and 46.7%), rhythm disturbance (19% and 17,8%), and impaired cardiac conduction (2.4% and 2.2%), IHD (2.4% and 8.9%), CF (7% and 15.5%). MI and myocarditis were diagnosed only in group 1 (4.4% and 9.5%, respectively); however, these differences were not statistically significant. AH was observed more frequently in group 2 than in group 1 (62.2% and 28.6%, р < 0.01); other TRFs did not demonstrate any differences; however, total cholesterol concentration and body mass index in group 2 were higher than in group 1: 5.7 and 4.5 mmol/L (р < 0.05); 22.66 and 22.10 kg/m2 (р < 0.01). NT-proBNP concentration in untreated patients was higher than in group 2 (150.7 and 32.6 pg/mL, respectively, р < 0.01), exceeding the normal values. Conclusion. Despite the juvenile age of patients, the therapy (mostly GC) and longer disease duration are associated with higher incidence of TRF (AH, hypercholesterolemia, overweight), while myocarditis and high NT-proBNP concentration are typical of untreated patients with highly active SLE. SLE patients should be followed up by a cardiologist; symptom-free CF markers should be identified as this condition is life-threatening, especially in patients with extremely active disease; TRFs should be monitored; and minimal GC doses should be used during remission/low-activity disease. Keywords: systemic lupus erythematosus; cardiac involvement; pericarditis; myocarditis; endocarditis; NT-proBNP; ECHO.

2 September 2024 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
AAAnastasia Avdeeva
Anastasia Avdeeva
Andrey AleksankinAndrey Aleksankin
Andrey Aleksankin
ETElena V Tchetina
Elena V Tchetina
YGYu. N. Gorbunova
Yu. N. Gorbunova
TVTatyana Popkova V.
Tatyana Popkova V.
ЕЧЕ. В. Четина
Е. В. Четина
The aim – to evaluate subpopulations of B lymphocytes and features of interferon (IFN) status in patients with systemic lupus erythematosus (SLE), to clarify the relationship of immunological parameters with clinical manifestations of the diseaseMaterial and methods. 139 patients (123 (88%) women and 16 (12%) men) with a definite diagnosis of SLE were included in the analysis. The disease duration was 3.0 [0.3; 12.0] years, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000) – 7 [4; 11] points, SDI (Systemic Lupus International Collaborating Clinics Damage Index) – 0 [0; 1] points. Immunophenotyping of peripheral blood lymphocytes, including determination of B cells, the general population of memory B cells, non-switched and switched memory B cells, naive, transient B cells, and plasmablasts was carried out using multicolor flow cytometry. IFN status was assessed by the expression of IFN-stimulated genes (MX1, RSAD2, EPSTI1) using real-time polymerase chain reactionResults. Two immunological “patterns” were identified – the prevailing immunological mechanism of the pathogenesis of the disease – SLE – with predominant activation of type I IFN and with predominant activation of the B cell component of the immune system. The immunological phenotype with activation of type I IFN was associated with high immunological activity, predominant skin damage, leukopenia, and the phenotype with predominant activation of the B cell link was associated with damage to the kidneys and nervous system.Conclusion. The results of the work suggest a wide variety of immune mechanisms underlying the pathogenesis of SLE. It is possible to identify a number of leading molecular “patterns” of the pathogenesis of the disease, which must be taken into account to select an effective “targeted” drug.

31 August 2025 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
AAAnastasia Avdeeva
Anastasia Avdeeva
MDM. E. Diatroptov
M. E. Diatroptov
YGYu. N. Gorbunova
Yu. N. Gorbunova
TVTatyana Popkova V.
Tatyana Popkova V.
TPT. A. Panafidina
T. A. Panafidina
ENE. L. Nasonov
E. L. Nasonov
The aim – to study the serum level of cytokines, chemokines, growth factors in patients with systemic lupus erythematosus (SLE) in comparison with healthy volunteers to identify promising indicators for assessing disease activity and the development of organ damage.Material and methods. The analysis included 139 patients (123 (88%) women and 16 (12%) men) with a reliable diagnosis of SLE. The median duration of the disease was 3.0 [0.3; 12.0] years, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index 2000) – 7 [4; 11] points, SDI (SLICC (Systemic Lupus International Collaborating Clinics) Damage Index) – 0 [0; 1] points. The study of 48 cytokines in blood serum was carried out by the method of multiplex immune analysis based on suspension microarray technology xMAP (Bio-Plex® 200 Pro Human Cytokine Screening Panel, 48-Plex; Bio-Rad Laboratories, USA) according to the manufacturer’s instructions. The control group consisted of 13 healthy donors, comparable in gender and age with the examined patients.Results. In patients with SLE, compared with healthy donors, there was a higher level of granulocyte colony-stimulating factor (G-CSF), interferon (IFN) γ, interleukin (IL) 6, IL-8, monocyte chemotactic protein (MCP) 1, IL-1 receptor antagonist (IL-1Ra), macrophage inflammatory protein (MIP) 1α, vascular endothelial growth factor (VEGF), IL-18, interferon-inducible protein 10 (IP-10), leukemia inhibitory factor (LIF), MCP-3, macrophage colony-stimulating factor (M-CSF), MIG (monokine induced by IFN-γ) (p<0.05). In the group of patients with nephritis (n=40), there was a higher concentration of IFN-γ, IL-7, VEGF, IFN-α2, M-CSF in contrast to patients without nephritis (p<0.05). Conclusion. In the sera of patients with SLE, a higher level of proinflammatory cytokines, chemokines, colony-stimulating, stromal and angiogenic factors is noted; M-CSF probably plays an important role in the development of nephritis. Further studies are required to improve our understanding of the role of cytokine profile parameters in the pathogenesis of SLE.

29 September 2017 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
TPT. A. Panafidina
T. A. Panafidina
MSM. A. Sokhova
M. A. Sokhova
TVTatyana Popkova V.
Tatyana Popkova V.
DND. S. Novikova
D. S. Novikova
EAE. N. Aleksandrova
E. N. Aleksandrova
AВArray В. Волков
Array В. Волков
Цель – определить уровень N-концевого фрагмента предшественника мозгового натрийуретического пептида В-типа (N-terminal fragment of brain natriuretic peptide progenitor, NT-proBNP) у пациентов с системной красной волчанкой (СКВ) до назначения иммуносупрессивной терапии, его возможную ассоциацию с иммуновоспалительными маркерами, традиционными факторами риска (ТФР) сердечно-сосудистых заболеваний (ССЗ) и показателями трансторакальной эхокардиографии (ЭхоКГ). Материал и методы. Включено 28 пациентов с СКВ (соответствующей критериям ACR 1997 г.), в том числе 23 (82%) женщины, медиана возраста – 28,5 [25,0; 32,0] года, без клинических признаков ССЗ и не получавших иммуносупрессивную терапию. Контрольную группу составили 27 здоровых доноров, сопоставимых с больными по возрасту и полу. Активность болезни оценивали по SLEDAI-2K, необратимые повреждения – по SLICC. Медиана длительности СКВ составила 21,0 [5,0; 60,0] мес, SLEDAI-2K – 11 [8; 19], SLICC/DI – 0 [0; 0] баллов. Определяли концентрацию С-реактивного белка (СРБ), интерлейкина 6 (ИЛ6) и фактора некроза опухоли α (ФНОα), проводили ЭхоКГ и оценку ТФР. Концентрацию NT-proBNP определяли в сыворотке крови методом электрохемилюминесценции (Roche Diagnostics, Швейцария). Нормальный диапазон уровня NT-proBNP составлял ≤125,0 пг/мл. Результаты и обсуждение. Больные СКВ имели повышенный уровень NT-proBNP по сравнению с контролем: соответственно 160,7 [88,6; 335,4] и 55,2 [36,6; 70,3] пг/мл (p125,0 пг/мл обнаружена у 18 (64%) больных СКВ. Пациенты были разделены на две группы: в первой концентрация NTproBNP была >125,0 пг/мл (n=18; 64%), во второй – не превышала этот уровень (n=10; 36%). Пациенты первой группы имели повышенные значения антител к кардиолипину (АКЛ) IgG (p<0,01), креатинина (p<0,05), конечного систолического размера (КСР) левого желудочка (ЛЖ; p<0,05), снижение фракции выброса (ФВ) ЛЖ (p<0,01), скорости клубочковой фильтрации (СКФ; p<0,05), концентрации антител к Ro-антигену (p<0,05), в сравнении с пациентами второй группы. У всех пациентов с диастолической дисфункцией миокарда ЛЖ (ДДЛЖ) (n=5; 18%) уровень NT-proBNP значительно превышал нормальные значения, его медиана составила 799,2 [276,6; 1777,0] пг/мл, но статистически значимого различия в частоте ДДЛЖ между группами не выявлено (р=0,066). У пациентов с СКВ уровень NT-proBNP положительно коррелировал с концентрацией креатинина (r=0,480; p<0,01), мочевой кислоты (r=0,427; p<0,05), АКЛ IgG (r=0,710; p<0,001), антител к двуспиральной ДНК (анти-дcДНК; r=0,395; p<0,05), антинуклеарных антител (АНА; r=0,256; p<0,05), показателями КСР ЛЖ (r=0,442; p<0,05), систолического давления в легочной артерии (СДЛА; r=0,486; p<0,05), отрицательно – с уровнем гемоглобина (r=-0,493; p<0,01), С4-компонента комплемента (r=-0,475; p<0,05), СКФ (r=-0,558; p<0,01) и ФВ (r=-0,505; p<0,01). Ассоциации уровня NT-proBNP с клиническими проявлениями СКВ (поражением кожи, слизистых оболочек, почек, нервной системы, артритом, серозитом, гематологическими нарушениями), а также с маркерами воспаления (СРБ, ИЛ6, ФНОα) не выявлено. Выводы. Концентрация NT-proBNP у пациентов с СКВ была значительно выше, чем в группе контроля (p125,0 пг/мл). Повышенный уровень NT-proBNP ассоциирован с иммунологическими показателями активности СКВ (увеличением содержания АКЛ IgG, анти-дcДНК, АНА, гипокомплементемией по С4-компоненту), маркерами, отражающими ухудшение функции почек и миокарда. Связи уровня NT-proBNP с клиническими проявлениями СКВ, маркерами воспаления (СРБ, ИЛ6, ФНОα) и ТФР не обнаружено.